JMP Securities downgraded Pardes Biosciences to Market Perform from Outperform without a price target. The analyst also terminated coverage of the name after Pardes announced this morning that it has agreed to be acquired by MediPacific for between $2.02 and $2.19 per share in cash, plus a contingent-value right for potential future value realization from Pardes’ coronavirus assets. The firm views a competing bid as unlikely.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRDS: